logo-loader

Imugene Limited releases new clinical data for HER-Vaxx cancer vaccine study

Published: 12:30 08 Jul 2019 AEST

Imugene Limited (ASX:IMU) chief executive officer Leslie Chong updates Proactive Investors on new clinical data from the Phase 1b study of its HER-Vaxx cancer vaccine after presenting at the European Society for Medical Oncology World Congress on gastrointestinal cancer in Spain over the weekend.

The data shows the cancer fighting antibody and clinical response rates continue to be positive in patients receiving the optimal biological dose of the vaccine.

Imugene’s HER-Vax is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor such as gastric, breast, ovarian, lung and pancreatic cancers.

Chong said the latest presentation for the vaccine further reinforced ongoing interest among the international oncology community in Imugene’s potentially revolutionary B-cell platform cancer vaccine and clinical development.

Imugene with Proactive at ASX Small and Mid Cap Conference

Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO and managing director Leslie Chong chats with Proactive's Jonathan Jackson live from the ASX Small and Mid Cap Conference in March 2024. The biotech stock is a clinical-stage immuno-oncology company that's developing a range of new and novel immunotherapies...

1 day, 12 hours ago